Screener
Aclaris Therapeutics ACRS Contingent consideration fair value adjustments
Contingent consideration fair value adjustments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Total costs and expenses | 25,867 | 20,185 | 50,055 | 39,724 |
| Loss from operations | (24,238) | (18,408) | (46,430) | (36,492) |
| Other income: | ||||
| Interest income | 1,761 | 2,018 | 3,275 | 4,184 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's contingent consideration fair value adjustments?
- Aclaris Therapeutics (ACRS) reported contingent consideration fair value adjustments of $300K in Q2 2026.
- How has Aclaris Therapeutics's contingent consideration fair value adjustments changed year-over-year?
- Aclaris Therapeutics's contingent consideration fair value adjustments decreased by 80.0% year-over-year, from $1.5M to $300K.
- What is the long-term trend for Aclaris Therapeutics's contingent consideration fair value adjustments?
- Over 3 years (2021 to 2025), Aclaris Therapeutics's contingent consideration fair value adjustments has grown at a -54.5% compound annual growth rate (CAGR), from $24.34M to $2.3M.
- What does contingent consideration fair value adjustments mean?
- Contingent consideration fair value adjustments
Ask your AI about Aclaris Therapeutics's contingent consideration fair value adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude